# Melanotan II: Pigment Signaling With a Serious Safety Record > Melanotan II: Research Overview — Age Defying Peptides — A cited literature summary of Melanotan II, a synthetic melanocortin peptide studied for pigment and appetite signaling — mechanism, case-report safety findings, and why it is unapproved and considered high-risk. **03 / SKIN & AESTHETICS RESEARCH** A synthetic melanocortin peptide studied for skin pigmentation and appetite — and the compound on this site with the most documented case reports of serious harm. ## The short version Melanotan II is a lab-made peptide, structurally related to a natural hormone called alpha-MSH, that activates receptors involved in skin pigmentation and appetite regulation. It is studied — not approved for any human use — because activating those same receptors can darken skin without sun exposure and can suppress appetite and affect sexual response. It has never completed the large, controlled trials required for approval anywhere, and it belongs on this site because pigmentation is one of the ways skin visibly changes with age and sun exposure, which is exactly the research question Melanotan II sits inside. This is also the compound on this site with the most serious documented safety findings. Published case reports describe new or darkening moles, melanoma, kidney injury, and priapism associated with its use [11][13]. None of that is a recommendation against research interest in the mechanism — it is why every claim on this page is handled with particular care, and why this page never frames Melanotan II as a tanning or cosmetic product. ## What it is Melanotan II is a cyclic (ring-shaped, chemically locked) seven-amino-acid analog of alpha-melanocyte-stimulating hormone (alpha-MSH), designed at the University of Arizona in the late 1980s to be more potent and more resistant to enzymatic breakdown than the natural hormone. Its full sequence is Ac-Nle4-cyclo[Asp5-His6-D-Phe7-Arg8-Trp9-Lys10]-NH2, with a molecular formula of C50H69N15O9. Unlike GHK-Cu, Melanotan II does not occur naturally in the body — it is an engineered analog built to activate melanocortin receptors more broadly and durably than alpha-MSH itself does, which is also part of why its effects extend well beyond skin, into appetite and sexual response, in ways the natural hormone does not to the same degree. ## How it works Melanotan II is a **non-selective agonist** of the melanocortin receptor family (MC1R through MC5R) — meaning it activates several related receptors at once rather than targeting just one. Activating MC1R on melanocytes, the skin's pigment-producing cells, raises a signaling molecule called cAMP and drives a cascade (PKA-CREB-MITF) that increases the enzyme tyrosinase and shifts pigment production toward eumelanin, the darker pigment type — producing skin and hair darkening without requiring UV exposure. Separately, activation of MC4R (and MC3R) in the hypothalamus and related brain circuits is what underlies the appetite-suppressing and pro-sexual effects studied in animal and early human research. Because the receptor activation is non-selective, a single dose of Melanotan II can plausibly touch pigmentation, appetite, and sexual response all at once — which is part of why its research and safety literature covers such a wide range of documented effects. ## What the research shows *Recent safety case report.* A 2026 case report documents reversible oral pigmentation in a man who self-administered Melanotan II (400 micrograms subcutaneously every other day for 64 days, a cumulative 12.8 mg): brown pigmentation appeared on the gums and inner cheek lining, with the cheek pigmentation beginning to fade within 28 days of stopping, while gum pigmentation was still present at reduced intensity three months later [11]. *Appetite mechanism.* In male mice, injecting a melanocortin agonist directly into a brain region called the nucleus accumbens significantly reduced food intake and reduced how hard the mice were willing to work for food, without producing the kind of taste aversion or metabolic-rate change that would suggest the animals simply felt sick [12]. *A documented kidney injury case.* A case report with literature review describes renal (kidney) infarction most likely attributable to Melanotan II use, noting that MT-II-associated rhabdomyolysis (severe muscle breakdown) and kidney failure had been described previously, and that both a clotting effect and a possible direct toxic effect on kidney tissue need to be considered as mechanisms [13]. *Historical and lineage context.* A 2006 review traces the lineage from the original Melanotan I (tested for skin tanning) through Melanotan II (tested for erectile dysfunction) to a further, separately developed analog that later advanced through its own clinical program for sexual dysfunction and gained its own distinct approval — a different, unapproved compound from Melanotan II, and this page is careful never to conflate the two [14]. *Controlled human trial for erectile response.* In a double-blind, placebo-controlled crossover study of 10 men with psychogenic erectile dysfunction, subcutaneous Melanotan II produced clinically apparent erections in 8 of 10 men, with an average of 38 minutes of substantial rigidity compared with 3 minutes for placebo — a statistically significant difference (p=0.0045) — alongside transient nausea, stretching, and yawning that resolved without treatment [15]. ## Reported effects, cautions & safety *Reported effects (anecdotal, not clinical evidence) — these are self-reported accounts from peptide-user forums and published qualitative research on online discussion, not measured outcomes, and this page includes no dose information from these sources.* The reason most people say they seek Melanotan II out is a rapid, deep tan with little or no sun exposure, with color developing within days. Reduced appetite and weight loss are very commonly reported, sometimes from the first dose — people are split on whether they consider this a welcome side effect or an unwanted one. Men frequently describe a sudden increase in libido and spontaneous erections, sometimes at inconvenient moments, while some report finding this uncomfortable rather than desirable; women also describe heightened arousal. Many people describe feeling more confident with the resulting tan, which is often cited as the reason they continue. The downsides reported are extensive and frequent. Nausea is one of the most consistently described effects, typically strongest in the first hour after a dose and easing with continued use. Facial flushing, spontaneous stretching and yawning, and a run-down "melanotan flu" feeling in the first days are all commonly mentioned. On pigmentation specifically, people very commonly report a blotchy or unevenly distributed tan that can linger for weeks to months, darkening of existing moles and freckles — often the first visible sign the peptide is working — and, more concerning, the appearance of entirely new moles, sometimes several at once, which users describe as what prompts them to see a doctor. *Cited safety cautions from the literature — this is the most serious safety profile of any compound on this site:* - **New, changing, or darkening moles, and melanoma risk.** Because Melanotan II is a non-selective melanocortin agonist, it drives melanocyte activity across the skin, and multiple published case reports describe new atypical moles, darkening of existing moles, and — in several documented cases — melanoma or melanoma in situ arising in people using melanotan products. Any new or changing mole during or after use warrants prompt evaluation by a dermatologist. - **Rhabdomyolysis and acute kidney injury**, including a documented case of renal infarction linked to Melanotan II use, with the underlying mechanism not fully understood but potentially related to the compound's effects on blood vessels [13]. - **Priapism** — a prolonged, painful erection that is a genuine medical emergency — has been described in several case reports following melanotan use, including after apparent overdose. - **Posterior reversible encephalopathy syndrome (PRES)**, a serious brain-swelling condition that can present with headache, seizures, and visual disturbance, has been described in a case report in association with melanotan use. - **Nausea and cardiovascular effects**, including a documented tendency for melanocortin agonists to raise blood pressure in preclinical work — a poorly characterized area in humans using unregulated product. - **Unregulated product: contamination and mislabeling.** Analytical studies of melanotan products bought online repeatedly find inaccurate labeling and variable, unverifiable content, meaning a buyer cannot actually know the identity, dose, purity, or sterility of what is in a given vial. - **No regulatory approval and unknown long-term safety.** Melanotan II has never been approved by the FDA or any other regulator for any use, and its development never completed the later-phase trials that would establish long-term human safety [14]. - **It is not a substitute for the separately approved melanocortin drugs it is sometimes confused with** — its lineage cousins that did complete approval processes for specific, narrow indications are different, distinct compounds, and their safety data do not extend to Melanotan II. ## Where it fits in Skin & Aesthetics research Melanotan II sits apart from the other two compounds on this site. Where [GHK-Cu](/ghk-cu) and the [GLOW blend](/glow) target the collagen and repair side of visible aging with a comparatively favorable safety record, Melanotan II targets pigment through a completely different receptor system, and its published research carries a far heavier weight of documented harm — melanoma, kidney injury, and priapism among them. Reading it alongside the other two is instructive precisely because the contrast is so stark: not every peptide studied in connection with skin aging carries the same risk profile, and this site treats that difference as the most important thing a reader should take away. See the [comparison page](/compare) for the three side by side. ![Melanotan II research illustration — abstract dermal-matrix and pigment motifs in violet](/images/melanotan-2.webp) --- A plainspoken literature desk on skin, pigment, and repair peptide research — citations and context, never a clinic, a vendor, or a prescription.